Skip to main content

Advertisement

SpringerLink
Log in

Antibody-based cancer therapies: back to “polyclonals”?

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ehrlich P. On immunity with special reference to cell life. In: Himmelweit F, Marquardt M, Dale H, editors. The collected papers of Paul Ehrlich, Volume II: Immunology and Cancer Research. Pergamon: London, 1957.

    Google Scholar 

  2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497.

    CAS  PubMed  Google Scholar 

  3. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35(1):122–128.

    Article  CAS  PubMed  Google Scholar 

  4. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German cancer Aid 17-1A study group. Lancet 1994;343(8907):1177–83.

    Article  CAS  PubMed  Google Scholar 

  5. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16(5):1788–94.

    CAS  PubMed  Google Scholar 

  6. Punt CJA, Nagy A, Douillaerd JY, et al. EdrecoloMoAb alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671–677.

    Article  CAS  PubMed  Google Scholar 

  7. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer 1998;78:478–83.

    CAS  PubMed  Google Scholar 

  8. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379–98.

    Article  CAS  PubMed  Google Scholar 

  9. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004;66(1–2):129–38.

    Article  PubMed  Google Scholar 

  10. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 2004;30(2):118–125.

    CAS  PubMed  Google Scholar 

  11. Yan C, Zhu ZG, Yu YY, Ji J, Zhang Y, Ji YB, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol 2004;10(6):783–790.

    CAS  PubMed  Google Scholar 

  12. Lim YJ, Lee JK, Park CK, Song SY, Jang WY, Ha HY, et al. Prognostic value of VEGF in human pancreatic ductal adenocarcinoma. Korean J Intern Med 2004;19(1):10–14.

    CAS  PubMed  Google Scholar 

  13. Ross JS, Gray K, Gray SG, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol 2003;119:472–485.

    Article  CAS  PubMed  Google Scholar 

  14. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van’t Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100(26):15901–5.

    Article  CAS  PubMed  Google Scholar 

  15. Goodiwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435–50.

    Article  PubMed  Google Scholar 

  16. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44(3):400–11.

    PubMed  Google Scholar 

  17. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Siccardi AG, Veronesi U. Antibody guided three-step therapy for high grade glioma with 90Y-biotin. Eur J Nucl Med 1999;26:348–57.

    Article  CAS  PubMed  Google Scholar 

  18. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002;86:207–12.

    Article  CAS  PubMed  Google Scholar 

  19. Paganelli G, Orecchia R, Jereczek-Fossa B, Grana C, Cremonesi M, De Braud F, et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med 1998;25:1336–9.

    Article  CAS  PubMed  Google Scholar 

  20. Grana C, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, et al. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with 90Y-biotin? Gynecol Oncol 2004;93:691–8.

    Article  CAS  PubMed  Google Scholar 

  21. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD-20-expressing lymphoma xenografts. Blood 2001;98:2535–43.

    Article  CAS  PubMed  Google Scholar 

  22. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004;45:867–77.

    PubMed  Google Scholar 

  23. De Santis R, Anastasi AM, D’ Alessio V, Pelliccia A, Albertoni C, Rosi A, et al. Novel antitenascin antibody with increased localisation for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Br J Cancer 2003;88:996–1003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy

    Giovanni Paganelli

  2. R&D-Pomezia, Sigma Tau SpA, Rome, Italy

    Rita De Santis

Authors
  1. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita De Santis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paganelli, G., De Santis, R. Antibody-based cancer therapies: back to “polyclonals”?. Eur J Nucl Med Mol Imaging 31, 1453–1455 (2004). https://doi.org/10.1007/s00259-004-1627-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1627-5

Search

Navigation